[Chemotherapy in non-small cell bronchial carcinoma. 12 years' experience in an international cooperative group: EORTC Lung Cancer Working Party].
The EORTC Lung Cancer Working Party investigates various chemotherapeutic regimens in patients with bronchogenic cancer. Within 12 years our Group has conducted 8 international co-operative studies in patients with non small cell lung cancer. We have demonstrated that Cis-platin was an active agent and its activity increases in association with Etoposide, mainly in limited disease. Lastly, we tested regimens including Carboplatin. This agent does not improve results in terms of objective response. We are now testing regimens including radiotherapy after chemotherapy in limited disease.
Lacroix
H
H
Service de pneumologie, hôpital G-R-Laennec, centre hospitalier universitaire de Nantes, France.
Sculier
J P
JP
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D014751:Vindesine / Q000008:administration & dosage
D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin; D014751:Vindesine
Chimiothérapie et carcinome bronchique non à petites cellules. Douze ans d'expérience au sein d'un groupe coopératif international: l'EORTC Lung Cancer Working Party.